PA8603601A1 - Nuevos derivados de indol como inhibidores del factor xa. - Google Patents

Nuevos derivados de indol como inhibidores del factor xa.

Info

Publication number
PA8603601A1
PA8603601A1 PA20048603601A PA8603601A PA8603601A1 PA 8603601 A1 PA8603601 A1 PA 8603601A1 PA 20048603601 A PA20048603601 A PA 20048603601A PA 8603601 A PA8603601 A PA 8603601A PA 8603601 A1 PA8603601 A1 PA 8603601A1
Authority
PA
Panama
Prior art keywords
factor
compounds
formula
inhibitors
factor viia
Prior art date
Application number
PA20048603601A
Other languages
English (en)
Inventor
Marc Nazare
Kurt Ritter
Volkmar Wehner
Volker Laux
Original Assignee
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh
Publication of PA8603601A1 publication Critical patent/PA8603601A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

ALA PRESENTEINVENCION SE REFIERE A COMPUESTOS DE LA FORMULA I, EN LA QUE R0; R1; R2; R3; R4; R5; R6; R7; Q; V, G Y M TIENE LOS SIGNIFICADOS INDICADOS EN LAS REIVINDICACIONES. LOS COMPUESTOS DE LA FORMULA I SON COMPUESTOS FARMACOLOGICAMENTE ACTIVOS VALIOSOS. MUESTRAN UN FUERTE EFECTO ANTITROMBOTICO Y SON ADECUADOS, POR EJEMPLO, PARA LA TERAPIA Y PROFILAXIS DE TRASTORNOS CARDIOVASCULARES TALES COMO ENFERMEDADES TROMBOEMBOLICAS O REESTENOSIS. SON INHIBIDORES REVERSIBLES DE LAS ENZIMAS DE LA COAGULACION SANGUINEA FACTOR XA (FXA) Y/A FACTOR VIIA (FVIIA) Y, EN GENERAL, PUEDEN APLICARSE EN SITUACIONES EN LAS QUE ESTA PRESENTE UNA ACTIVIDAD INDESEADA DEL FACTOR XA Y/O FACTOR VII O EN SITUACIONES PARA CUYA CURACION O PREVENCION SE DESEA LA INHIBICION DEL FACTOR XA Y/O FACTOR VIIA. ADEMAS, LA INVENCION SE REFIERE A PROCESOS PARA LA PREPARACION DE COMPUESTOS DE LA FORMULA I, A SU USO, EN PARTICULAR COMO INGREDIENTES ACTIVOS EN PRODUCTOS FARMACEUTICOS, Y A PREPARACIONES FARMACEUTICAS QUE LOS CONTIENEN
PA20048603601A 2003-05-19 2004-05-19 Nuevos derivados de indol como inhibidores del factor xa. PA8603601A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP03011306A EP1479677A1 (en) 2003-05-19 2003-05-19 New indole derivatives as factor xa inhibitors

Publications (1)

Publication Number Publication Date
PA8603601A1 true PA8603601A1 (es) 2004-11-26

Family

ID=33040953

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20048603601A PA8603601A1 (es) 2003-05-19 2004-05-19 Nuevos derivados de indol como inhibidores del factor xa.

Country Status (15)

Country Link
US (1) US7196103B2 (es)
EP (2) EP1479677A1 (es)
JP (1) JP4676960B2 (es)
AT (1) ATE475659T1 (es)
AU (1) AU2004238495B2 (es)
BR (1) BRPI0410466A (es)
CA (1) CA2526066A1 (es)
CL (1) CL2004001074A1 (es)
DE (1) DE602004028367D1 (es)
MX (1) MXPA05012232A (es)
PA (1) PA8603601A1 (es)
PE (1) PE20050156A1 (es)
TW (1) TW200510393A (es)
UY (1) UY28325A1 (es)
WO (1) WO2004101554A1 (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1314733A1 (en) * 2001-11-22 2003-05-28 Aventis Pharma Deutschland GmbH Indole-2-carboxamides as factor Xa inhibitors
US7358268B2 (en) * 2002-12-04 2008-04-15 Sanofi-Aventis Deutschland Gmbh Imidazole derivatives as factor Xa inhibitors
US7429581B2 (en) 2002-12-23 2008-09-30 Sanofi-Aventis Deutschland Gmbh Pyrazole-derivatives as factor Xa inhibitors
US7741341B2 (en) 2003-05-19 2010-06-22 Sanofi-Aventis Deutschland Gmbh Benzimidazole-derivatives as factor Xa inhibitors
EP1479675A1 (en) * 2003-05-19 2004-11-24 Aventis Pharma Deutschland GmbH Indazole-derivatives as factor Xa inhibitors
US7317027B2 (en) * 2003-05-19 2008-01-08 Sanofi-Aventis Deutschland Gmbh Azaindole-derivatives as factor Xa inhibitors
EP1479677A1 (en) 2003-05-19 2004-11-24 Aventis Pharma Deutschland GmbH New indole derivatives as factor xa inhibitors
US7223780B2 (en) * 2003-05-19 2007-05-29 Sanofi-Aventis Deutschland Gmbh Triazole-derivatives as blood clotting enzyme factor Xa inhibitors
EP1571154A1 (en) * 2004-03-03 2005-09-07 Aventis Pharma Deutschland GmbH Beta-aminoacid-derivatives as factor Xa inhibitors
FR2888847B1 (fr) * 2005-07-22 2007-08-31 Sanofi Aventis Sa Derives de n-(heteriaryl)-1-heteorarylalkyl-1h-indole-2- carboxamides, leur preparation et application en therapeutique
US7977359B2 (en) 2005-11-04 2011-07-12 Amira Pharmaceuticals, Inc. 5-lipdxygenase-activating protein (FLAP) inhibitors
GB2431927B (en) 2005-11-04 2010-03-17 Amira Pharmaceuticals Inc 5-Lipoxygenase-activating protein (FLAP) inhibitors
SI3095447T1 (sl) 2006-02-03 2022-02-28 Opko Renal, Llc Zdravljenje pomanjkanja vitamina D s 25-hidroksivitaminom D2 in 25-hidroksivitaminom D3
PT2679228T (pt) 2006-06-21 2018-04-16 Opko Ireland Global Holdings Ltd Terapia utilizando um agente de repleção de vitamina d e um agente de substituição hormonal de vitamina d
PT2148661E (pt) 2007-04-25 2013-03-06 Proventiv Therapeutics Llc Composições orais de libertação controlada compreendendo um composto de vitamina d e veículo ceroso
EP3335712A1 (en) 2007-04-25 2018-06-20 Opko Renal, LLC Method of safely and effectively treating and preventing secondary hyperparathyroidism in chronic kidney disease
TW200920369A (en) 2007-10-26 2009-05-16 Amira Pharmaceuticals Inc 5-lipoxygenase activating protein (flap) inhibitor
ES2523580T3 (es) * 2008-01-11 2014-11-27 Albany Molecular Research, Inc. Piridoindoles substituidos con (1-Azinona)
CN106853250A (zh) 2008-04-02 2017-06-16 赛特克罗公司 用于维生素d缺乏症和相关障碍的方法、组合物、用途和试剂盒
SG190667A1 (en) 2008-05-23 2013-06-28 Panmira Pharmaceuticals Llc 5-lipoxygenase-activating protein inhibitor
AU2010241567B2 (en) 2009-04-29 2013-10-31 Amarin Pharmaceuticals Ireland Limited Pharmaceutical compositions comprising EPA and a cardiovascular agent and methods of using the same
WO2011003012A1 (en) * 2009-07-01 2011-01-06 Albany Molecular Research, Inc. Azinone-substituted azapolycycle mch-1 antagonists, methods of making, and use thereof
WO2011003021A1 (en) * 2009-07-01 2011-01-06 Albany Molecular Research, Inc. Azinone-substituted azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine mch-1 antagonists, methods of making, and use thereof
WO2011003007A1 (en) * 2009-07-01 2011-01-06 Albany Molecular Research, Inc. Azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine mch-1 antagonists, methods of making, and use thereof
EP2448585B1 (en) * 2009-07-01 2014-01-01 Albany Molecular Research, Inc. Azinone-substituted azepino[b]indole and pyrido-pyrrolo-azepine mch-1 antagonists, methods of making, and use thereof
PT2552484T (pt) 2010-03-29 2020-04-03 Opko Ireland Global Holdings Ltd Métodos e composições para redução dos níveis de parafróides
WO2012088038A2 (en) 2010-12-21 2012-06-28 Albany Molecular Research, Inc. Piperazinone-substituted tetrahydro-carboline mch-1 antagonists, methods of making, and uses thereof
WO2012088124A2 (en) 2010-12-21 2012-06-28 Albany Molecular Research, Inc. Tetrahydro-azacarboline mch-1 antagonists, methods of making, and uses thereof
KR101847947B1 (ko) 2013-03-15 2018-05-28 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 안정화되고 변형된 비타민 ｄ 방출 제형
EP3193925A2 (en) 2014-08-07 2017-07-26 OPKO Ireland Global Holdings, Ltd. Adjunctive therapy with 25-hydroxyvitamin d
MX2018011820A (es) 2016-03-28 2019-01-24 Opko Ireland Global Holdings Ltd Metodos de tratamiento con vitamina d.

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11469A (en) * 1854-08-08 boynton
US4675332A (en) * 1984-12-10 1987-06-23 Warner-Lambert Company Acidic tetrazolyl substituted indole compounds and their use as antiallergy agents
JPH0287282A (ja) * 1988-09-22 1990-03-28 Nec Corp グラフ作図レイアウト決定方式
US5506134A (en) 1990-10-22 1996-04-09 Corvas International, Inc. Hypridoma and monoclonal antibody which inhibits blood coagulation tissue factor/factor VIIa complex
US5833982A (en) 1991-02-28 1998-11-10 Zymogenetics, Inc. Modified factor VII
US5788965A (en) 1991-02-28 1998-08-04 Novo Nordisk A/S Modified factor VII
TW229140B (es) * 1992-06-05 1994-09-01 Shell Internat Res Schappej B V
CN1181091C (zh) 1994-04-26 2004-12-22 西莱克泰德公司 因子Xa抑制剂
FR2763337B1 (fr) * 1997-05-13 1999-08-20 Sanofi Sa Nouveaux derives du triazole, un procede pour leur preparation et compositions pharmaceutiques les contenant
US20040043995A1 (en) 1997-05-13 2004-03-04 Eric Bignon Novel triazole derivatives, process for their preparation and pharmaceutical compositions containing them
BR9814340B1 (pt) * 1997-12-24 2010-07-13 compostos derivados de indol, processo para a preparação dos mesmo e composição farmacêutica.
WO2000007591A1 (en) * 1998-08-03 2000-02-17 Eli Lilly And Company INDOLE sPLA2 INHIBITORS
EP0987274A1 (en) 1998-09-15 2000-03-22 Hoechst Marion Roussel Deutschland GmbH Factor VIIa Inhibitors
US6486211B1 (en) * 1999-10-22 2002-11-26 Smithkline Beecham Corporation Indole compounds
US7053070B2 (en) * 2000-01-25 2006-05-30 Warner-Lambert Company Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors
US6436965B1 (en) * 2000-03-02 2002-08-20 Merck Frosst Canada & Co. PDE IV inhibiting amides, compositions and methods of treatment
UA72625C2 (uk) * 2000-05-26 2005-03-15 Ніппон Сіняку Ко., Лтд. Гетероциклічні сполуки
EP1289952A1 (en) * 2000-05-31 2003-03-12 AstraZeneca AB Indole derivatives with vascular damaging activity
US20030165837A1 (en) 2000-06-14 2003-09-04 The Scripps Research Institute Method for screening DNA binding
WO2001096313A1 (en) * 2000-06-14 2001-12-20 The Scripps Research Institute Distamycin a analogs
US6525202B2 (en) * 2000-07-17 2003-02-25 Wyeth Cyclic amine phenyl beta-3 adrenergic receptor agonists
EP1217000A1 (en) 2000-12-23 2002-06-26 Aventis Pharma Deutschland GmbH Inhibitors of factor Xa and factor VIIa
DE10147672A1 (de) * 2001-09-27 2003-04-10 Bayer Ag Substituierte 2,5-Diamidoindole und ihre Verwendung
US7064135B2 (en) * 2001-10-12 2006-06-20 Novo Nordisk Inc. Substituted piperidines
EP1314733A1 (en) * 2001-11-22 2003-05-28 Aventis Pharma Deutschland GmbH Indole-2-carboxamides as factor Xa inhibitors
US7358268B2 (en) 2002-12-04 2008-04-15 Sanofi-Aventis Deutschland Gmbh Imidazole derivatives as factor Xa inhibitors
US7429581B2 (en) 2002-12-23 2008-09-30 Sanofi-Aventis Deutschland Gmbh Pyrazole-derivatives as factor Xa inhibitors
US7078419B2 (en) * 2003-03-10 2006-07-18 Boehringer Ingelheim Pharmaceuticals, Inc. Cytokine inhibitors
US7049323B2 (en) * 2003-04-25 2006-05-23 Bristol-Myers Squibb Company Amidoheterocycles as modulators of the melanocortin-4 receptor
EP1479677A1 (en) 2003-05-19 2004-11-24 Aventis Pharma Deutschland GmbH New indole derivatives as factor xa inhibitors
EP1479675A1 (en) 2003-05-19 2004-11-24 Aventis Pharma Deutschland GmbH Indazole-derivatives as factor Xa inhibitors
US7223780B2 (en) 2003-05-19 2007-05-29 Sanofi-Aventis Deutschland Gmbh Triazole-derivatives as blood clotting enzyme factor Xa inhibitors
US7741341B2 (en) 2003-05-19 2010-06-22 Sanofi-Aventis Deutschland Gmbh Benzimidazole-derivatives as factor Xa inhibitors
US7405670B2 (en) * 2005-07-29 2008-07-29 Fitzgerald Timothy W Method and system for detecting and isolating stray voltage

Also Published As

Publication number Publication date
DE602004028367D1 (de) 2010-09-09
EP1479677A1 (en) 2004-11-24
AU2004238495B2 (en) 2010-07-22
MXPA05012232A (es) 2006-08-18
UY28325A1 (es) 2004-12-31
BRPI0410466A (pt) 2006-05-30
JP4676960B2 (ja) 2011-04-27
EP1633746A1 (en) 2006-03-15
PE20050156A1 (es) 2005-04-27
AU2004238495A1 (en) 2004-11-25
CL2004001074A1 (es) 2005-03-28
TW200510393A (en) 2005-03-16
US20050033049A1 (en) 2005-02-10
WO2004101554A1 (en) 2004-11-25
ATE475659T1 (de) 2010-08-15
US7196103B2 (en) 2007-03-27
CA2526066A1 (en) 2004-11-25
JP2006528940A (ja) 2006-12-28
EP1633746B1 (en) 2010-07-28

Similar Documents

Publication Publication Date Title
UY28325A1 (es) Nuevos derivados de indol como inhibidores del factor xa
PE20050153A1 (es) DERIVADOS DE INDAZOL COMO INHIBIDORES DEL FACTOR Xa
PT1349847E (pt) Novos derivados de oxibenzamidas como inibidores do factor xa
RS40404A (en) Indole-2-carboxamides as factor xa inhibitors
TW200505914A (en) Pyrazole-derivatives as factor Xa inhibitors
BRPI0508048A (pt) derivados de pirrol como inibidores do fator xa
IL171843A (en) TRIAZOLE DERIVATIVES AS FACTOR Xa INHIBITORS
TNSN05297A1 (en) BENZIMIDAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS
YU29702A (sh) N-gvanidinoalkilamidi, njihovo dobijanje, njihova primena i farmaceutski preparati koji ih obuhvataju
TNSN05296A1 (en) AZAINDOLE-DERIVATIVES AS FACTOR Xa INHIBITORS
TW200504027A (en) Imidazole-derivatives as factor Xa inhibitors
TW200716620A (en) Heteroaryl-carboxylic acid (sulfamoyl alkyl) amide-derivatives as factor Xa inhibitors
JO2467B1 (en) New indole derivatives as an inhibitor of Xa